Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012:2012:978396.
doi: 10.1155/2012/978396. Epub 2012 Jul 9.

Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?

Karina I Halilova  1 , Elizabeth E Brown, Sarah L Morgan, S Louis Bridges Jr, Min-Ho Hwang, Donna K Arnett, Maria I Danila
Affiliations

Markers of treatment response to methotrexate in rheumatoid arthritis: where do we stand?

Karina I Halilova et al. Int J Rheumatol. 2012.

Abstract

Methotrexate (MTX) is the most commonly used disease-modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, despite its efficacy and affordability, additional DMARDs or biologic agents are often required in order to achieve the recommended goals of low disease activity or remission. Although well tolerated by most, some patients develop important side effects such as cytopenias, gastrointestinal adverse events (stomatitis, nausea), or abnormal liver function tests, which may limit its use and may result in additional health care costs. Given the clinical implications of widespread use of MTX in RA, various studies have evaluated the role of potential biomarkers in predicting treatment effectiveness of MTX. These biomarkers include RBC MTX polyglutamate (PG) levels; genetic variation in genes from relevant biological and metabolic pathways; gene expression profiles; serum proteins. This paper provides an update on the current data regarding biomarkers of treatment response to MTX.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Methotrexate cellular disposition and effects from reference [9]. Copyright PharmGKBu, Used with permission from PharmGKB and Stanford University.
See this image and copyright information in PMC

References

    1. Morgan SL, Oster RA, Lee JY, Alarcón GS, Baggott JE. The effect of folic acid and folinic acid supplements on purine metabolism in methotrexate-treated rheumatoid arthritis. Arthritis & Rheumatism. 2004;50(10):3104–3111. - PubMed
    1. Wessels JA, Huizinga TW, Guchelaar HJ. Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis. Rheumatology. 2008;47(3):249–255. - PubMed
    1. Jeurissen ME, Boerbooms AM, Van De Putte LB, Doesburg WH, Lemmens AM. Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis: a randomized, double-blind study. Annals of Internal Medicine. 1991;114(12):999–1004. - PubMed
    1. Krause D, Schleusser B, Herborn G, Rau R. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis & Rheumatism. 2000;43(1):14–21. - PubMed
    1. Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F. Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature. International Journal of Rheumatology. 2011;2011:6 pages.845496 - PMC - PubMed

LinkOut - more resources